Cipla Ltd

Cipla Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Cipla Ltd

₹ 1,401 -1.21%
29 May - close price
cipla.com BSE: 500087 NSE: CIPLA
About

Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]

Key Points

Market Leadership[1]
# 3rd largest in the India domestic Rx market
# Leadership in Gx
# 1st rank in Respiratory
# Top 5 in Urology and Anti-infectives.
# Over 5 Lac+ no of downloads - Digital Breathe free
# 7,500+ field force detailing to HCPs across the country – 85% of physicians prescribe at least one Cipla product.
# 3rd largest player in private Rx market in SAGA
# Fastest growing generic player in North America.

Website BSE NSE
  • Market Cap ₹ 1,13,173 Cr.
  • Current Price ₹ 1,401
  • High / Low ₹ 1,673 / 1,166
  • Stock P/E 27.8
  • Book Value ₹ 426
  • Dividend Yield 0.93 %
  • ROCE 16.6 %
  • ROE 12.4 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 25.7%

Cons

  • The company has delivered a poor sales growth of 8.01% over past five years.
  • Promoter holding has decreased over last 3 years: -4.34%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty 50 BSE 500 BSE Healthcare BSE 100 BSE 200

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
5,739 6,329 6,678 6,604 6,163 6,694 7,051 7,073 6,730 6,957 7,589 7,074 6,541
4,566 4,835 4,944 4,856 4,847 4,978 5,165 5,084 5,192 5,179 5,695 5,819 5,586
Operating Profit 1,174 1,494 1,734 1,748 1,316 1,716 1,886 1,989 1,538 1,778 1,895 1,255 955
OPM % 20% 24% 26% 26% 21% 26% 27% 28% 23% 26% 25% 18% 15%
-48 136 176 -10 249 160 191 222 289 259 269 -70 148
Interest 34 16 26 30 18 18 15 15 14 14 13 14 13
Depreciation 346 239 290 233 288 247 272 280 309 253 297 278 383
Profit before tax 745 1,375 1,594 1,474 1,259 1,611 1,789 1,916 1,504 1,770 1,854 893 707
Tax % 30% 28% 28% 28% 26% 27% 27% 17% 19% 27% 27% 24% 22%
522 998 1,155 1,068 932 1,175 1,305 1,575 1,214 1,292 1,353 674 543
EPS in Rs 6.51 12.33 14.01 13.08 11.63 14.58 16.13 19.45 15.13 16.06 16.73 8.37 6.87
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
11,345 13,790 14,394 15,156 16,362 17,132 19,160 21,763 22,753 25,774 27,548 28,163
9,183 11,310 11,898 12,329 13,265 13,926 14,907 17,211 17,726 19,483 20,420 22,280
Operating Profit 2,163 2,480 2,496 2,826 3,097 3,206 4,252 4,553 5,027 6,291 7,128 5,883
OPM % 19% 18% 17% 19% 19% 19% 22% 21% 22% 24% 26% 21%
164 208 208 280 477 344 266 99 293 552 862 606
Interest 168 207 159 114 168 197 161 106 110 90 62 54
Depreciation 505 754 1,323 1,323 1,326 1,175 1,068 1,052 1,172 1,051 1,107 1,211
Profit before tax 1,654 1,727 1,222 1,669 2,079 2,178 3,290 3,493 4,038 5,702 6,821 5,224
Tax % 24% 19% 15% 15% 27% 29% 27% 27% 30% 27% 22% 26%
1,229 1,383 1,035 1,417 1,492 1,500 2,389 2,547 2,833 4,154 5,269 3,862
EPS in Rs 14.71 16.93 12.51 17.52 18.96 19.18 29.82 31.19 34.71 51.05 65.28 48.02
Dividend Payout % 14% 12% 16% 17% 16% 21% 17% 16% 24% 25% 25% 27%
Compounded Sales Growth
10 Years: 7%
5 Years: 8%
3 Years: 7%
TTM: 2%
Compounded Profit Growth
10 Years: 12%
5 Years: 11%
3 Years: 13%
TTM: -21%
Stock Price CAGR
10 Years: 12%
5 Years: 8%
3 Years: 13%
1 Year: -4%
Return on Equity
10 Years: 13%
5 Years: 15%
3 Years: 15%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 161 161 161 161 161 161 161 161 161 161 162 162
Reserves 10,641 11,356 12,383 14,068 14,851 15,602 18,165 20,680 23,246 26,545 31,032 34,270
1,703 5,202 4,113 4,098 4,316 2,816 2,014 1,056 803 559 438 614
3,166 4,331 4,213 4,346 4,433 4,843 4,514 4,960 5,089 5,267 5,702 7,450
Total Liabilities 15,670 21,049 20,869 22,673 23,762 23,423 24,855 26,857 29,300 32,533 37,334 42,496
6,830 9,368 9,492 9,950 9,608 9,683 9,516 9,683 9,160 9,607 10,006 12,890
CWIP 581 2,061 1,683 981 676 825 969 766 1,093 1,153 1,566 1,586
Investments 640 759 973 1,259 2,554 1,471 2,710 2,551 3,662 5,449 7,933 8,223
7,620 8,862 8,721 10,483 10,923 11,444 11,661 13,857 15,384 16,323 17,828 19,796
Total Assets 15,670 21,049 20,869 22,673 23,762 23,423 24,855 26,857 29,300 32,533 37,334 42,496

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,173 1,741 2,382 1,463 1,691 3,068 3,755 3,326 3,238 4,134 5,005 3,940
-950 -4,533 -1,304 -834 -1,688 114 -2,374 -1,858 -2,376 -2,982 -3,682 -2,326
165 3,104 -1,326 -385 -349 -2,949 -1,240 -1,600 -958 -1,200 -1,293 -1,234
Net Cash Flow 388 312 -248 243 -345 234 141 -132 -97 -49 30 380
Free Cash Flow 548 688 1,284 723 1,187 2,083 2,964 2,645 2,102 2,819 3,490 928
CFO/OP 72% 91% 113% 77% 74% 122% 113% 98% 90% 91% 94% 94%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 64 62 65 75 93 83 66 57 65 68 73 73
Inventory Days 329 273 239 271 250 267 232 230 228 217 231 252
Days Payable 126 106 108 142 123 139 103 108 112 102 116 123
Cash Conversion Cycle 267 230 196 204 220 211 195 180 181 182 188 202
Working Capital Days 89 -10 99 118 132 113 94 95 113 120 128 205
ROCE % 15% 13% 7% 9% 11% 12% 17% 17% 18% 23% 23% 17%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Spend as % of Revenue
%

Log in to view insights

Please log in to see hidden values.

Login
Number of Brands with revenue > INR 100 Crore in India
Count
Brands in Top 300 of IPM
Count
Cumulative ANDAs/NDAs Filed (US)
Count
India Pharmaceutical Market (IPM) Market Share
%
Manufacturing Facilities
Count
South Africa Private Market Share
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
33.46% 33.46% 33.46% 33.46% 30.91% 30.93% 29.19% 29.20% 29.19% 29.22% 29.22% 29.22%
25.49% 25.74% 25.73% 25.82% 27.82% 28.80% 26.65% 26.28% 25.24% 24.54% 23.93% 22.55%
24.05% 23.90% 24.05% 24.15% 24.66% 23.95% 27.49% 27.89% 28.98% 29.98% 30.45% 31.71%
0.21% 0.21% 0.21% 0.21% 0.21% 0.21% 0.23% 0.26% 0.27% 0.27% 0.27% 0.27%
16.76% 16.68% 16.53% 16.36% 16.40% 16.11% 16.43% 16.36% 16.30% 15.99% 16.12% 16.26%
No. of Shareholders 4,66,5154,26,8634,25,7314,36,1544,63,5694,70,2345,25,1145,43,4205,49,6555,34,5875,40,5215,84,217

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls